

dollar amount of the total costs of the project or program that will be financed by non-governmental sources.

### 3. Reporting Requirements

The applicant must provide HHS with an original, plus two hard copies, as well as an electronic copy of the following reports in English:

1. A quarterly progress report, due no less than 30 days after the end of each quarter of the budget period. The progress report for the third quarter of the year will serve as the non-competing continuation application. The quarterly progress report must contain the following elements:

- a. Activities and Objectives for the Current Budget Period;
- b. Financial Progress for the Current Budget Period;
- c. Proposed Activity Objectives for the New Budget Period;
- d. Budget;
- e. Measures of Effectiveness; and
- f. Additional Requested Information.

2. An annual progress report, due 90 days after the end of the budget period, which must contain a detailed summary of the elements required in the quarterly progress report;

3. Final performance reports, due no more than 90 days after the end of the project period; and

4. A Financial Status Report (FSR) SF-269 is due 90 days after the close of each 12-month budget period.

Recipients must mail the reports to the Grants Management Specialist listed in the "Agency Contacts" section of this announcement.

### VII. Agency Contacts

For program technical assistance, contact: Lily O. Engstrom, Senior Policy Advisor to the Assistant Secretary for Public Health Emergency Preparedness, Office of Public Health Emergency Preparedness, OS, HHS, Telephone: 202.205.4727, E-mail: [lily.engstrom@hhs.gov](mailto:lily.engstrom@hhs.gov).

For financial, grants management, or budget assistance, contact: Grants Management Specialist, Office of Grants Management, Office of Public Health and Science, 11101 Wootten Parkway, Suite 550, Rockville, MD 20857, Telephone: (240) 453-8822, E-mail Address: [kcampbell@osophs.dhhs.gov](mailto:kcampbell@osophs.dhhs.gov).

Dated: March 2, 2006.

**Stewart Simonson,**

*Assistant Secretary for Public Health Emergency Preparedness, Department of Health and Human Services.*

[FR Doc. E6-3251 Filed 3-7-06; 8:45 am]

BILLING CODE 4150-37-P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Healthcare Research and Quality

#### Meeting of the National Advisory Council for Healthcare Research and Quality

**AGENCY:** Agency for Healthcare Research and Quality (AHRQ), HHS.

**ACTION:** Notice of public meeting.

**SUMMARY:** In accordance with section 10(a) of the Federal Advisory Committee Act, this notice announces a meeting of the National Advisory Council for Healthcare Research and Quality.

**DATES:** The meeting will be held on Friday, April 7, 2006, from 8:30 a.m. to 4 p.m. and is open to the public.

**ADDRESSES:** The meeting will be held in Room 800, the Department of Health and Human Services, Hubert H. Humphrey Building, 200 Independence Avenue, SW., Washington, DC 20201.

**FOR FURTHER INFORMATION CONTACT:** Deborah Queenan, Coordinator of the Advisory Council, at the Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland, 20850, (301) 427-1330. For press-related information, please contact Karen Migdail at (301) 427-1855.

If sign language interpretation or other reasonable accommodation for a disability is needed, please contact Mr. Donald L. Inniss, Director, Office of Equal Employment Opportunity Program, Program Support Center, on (301) 443-1144 no later than March 24, 2006. Agenda, roster, and minutes from previous council meetings are available from Ms. Bonnie Campbell, Committee Management Officer, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland, 20850. Ms. Campbell's phone number is (301) 427-1554.

#### SUPPLEMENTARY INFORMATION:

##### I. Purpose

Section 921 of the Public Health Service Act (42 U.S.C. 299c) established the National Advisory Council for Healthcare Research and Quality. In accordance with its statutory mandate, the Council is to advise the Secretary of the Department of Health and Human Services and the Director, Agency for Healthcare Research and Quality (AHRQ), on matters related to actions of the Agency to enhance the quality, improve the outcomes, reduce the costs of health care services, improve access to such services through scientific research, and to promote improvements in clinical practice and in the

organization, financing, and delivery of health care services.

The Council is composed of members of the public appointed by the Secretary, and Federal ex-officio members.

## II. Agenda

On Friday, April 7, 2006, the meeting will convene at 8:30 a.m. with the call to order by the Council Chair. The agenda will include the Director's update on the status of the Agency's current research, programs, and initiatives; a discussion of ambulatory care safety; and the findings on breast cancer from AHRQ's Effective Healthcare initiative. The official agenda will be available on AHRQ's Web site at <http://www.ahrq.gov> no later than March 31, 2006.

The meeting will adjourn at 4 p.m.

Dated: February 27, 2006.

**Carolyn M. Clancy,**

*Director.*

[FR Doc. 06-2189 Filed 3-7-06; 8:45 am]

BILLING CODE 4160-90-M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Clinical Laboratory Improvement Advisory Committee: Notice of Charter Renewal

This gives notice under the Federal Advisory Committee Act (Pub. L. 92-463) of October 6, 1972, that the Clinical Laboratory Improvement Advisory Committee, Centers for Disease Control and Prevention, of the Department of Health and Human Services, has been renewed for a 2-year period extending through February 19, 2008.

For further information, contact Robert Martin, M.D., Executive Secretary, Centers for Disease Control and Prevention, Department of Health and Human Services, 4470 Buford Highway, M/S G-25, Chamblee, Georgia 30341, telephone 770-488-8295 or fax 7770-488-8282.

The Director, Management and Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Dated: March 2, 2006.

**Alvin Hall,**

Director, Management Analysis and Services  
Office, Centers for Disease Control and  
Prevention.

[FR Doc. E6-3261 Filed 3-7-06; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**Centers for Disease Control and  
Prevention**

**Government-Owned Inventions;  
Availability for Licensing and  
Cooperative Research and  
Development Agreements (CRADAs)**

**AGENCY:** Centers for Disease Control and  
Prevention Technology Transfer Office;  
Department of Health and Human  
Services.

**ACTION:** Notice.

**SUMMARY:** The invention named in this  
notice is owned by agencies of the  
United States Government and is  
available for licensing in the United  
States (U.S.) in accordance with 35  
U.S.C. 207, and is available for  
cooperative research and development  
agreements (CRADAs) in accordance  
with 15 U.S.C. 3710a, to achieve  
expeditious commercialization of  
results of federally funded research and  
development. A provisional patent  
application has been filed. A Patent  
Cooperation Treaty (PCT) application  
and national stage foreign patent  
applications claiming priority to the  
Patent Cooperation Treaty (PCT)  
application are expected to be filed  
within the appropriate deadlines to  
extend market coverage for U.S.  
companies and may also be available for  
licensing.

**ADDRESSES:** Licensing and CRADA  
information, and information related to  
the technology listed below, may be  
obtained by writing to Suzanne Seavello  
Shope, J.D., Technology Licensing and  
Marketing Scientist, Technology  
Transfer Office, Centers for Disease  
Control and Prevention (CDC), Mailstop  
K-79, 4770 Buford Highway, Atlanta,  
GA 30341, telephone (770)488-8613;  
facsimile (770)488-8615; or e-mail  
[sshope@cdc.gov](mailto:sshope@cdc.gov). A signed Confidential  
Disclosure Agreement (available under  
Forms at <http://www.cdc.gov/tto>) will be  
required to receive copies of  
unpublished patent applications and  
other information.

**Diagnostics**

*Immunoassay for Diagnosis of  
Orthopoxvirus Infection*

A CDC-developed immunoassay may  
be used for the diagnosis of infection  
with Orthopoxviruses (e.g. Monkeypox,  
Variola) by detection of acute phase  
immune responses that correlate to  
recent infection. With recent recognition  
of Orthopox viruses as emerging  
infectious agents with zoonotic  
transmission capabilities as well as  
select agents for bioterrorism, assays for  
the detection or diagnosis of infections  
are sought. This assay provides a rapid  
and simple method for detection of  
infection with these viruses related to  
zoonotic transmission or bioterrorism  
events involving such viruses.

Use of the assay produced high levels  
of sensitivity during the 2003  
Monkeypox outbreak in North America  
when compared to PCR. Commercialization  
of the ELISA test may provide a standard  
screening tool for diagnosis of  
Orthopoxvirus as well as a surveillance  
tool for exposure.

The immunoassay may also be useful  
at the state level for BT surveillance  
including an opportunity for use in  
reference labs. Reagents used in the  
assay are available through CDC  
laboratories and for commercial  
development of the assay. Further  
refinement of the assay may result in  
the development of additional reagents  
for incorporation into the assay.

*Inventors:* Kevin L. Karem, Inger K.  
Damon and Joanne L. Patton.  
*CDC Ref. #:* I-014-04.

**James D. Seligman,**

Chief Information Officer, Centers for Disease  
Control and Prevention.

[FR Doc. E6-3267 Filed 3-7-06; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND  
HUMAN SERVICES**

**Centers for Disease Control and  
Prevention**

**Government-Owned Inventions;  
Availability for Licensing and  
Cooperative Research and  
Development Agreements (CRADAs)**

**AGENCY:** Centers for Disease Control and  
Prevention, Technology Transfer Office,  
Department of Health and Human  
Services.

**ACTION:** Notice.

**SUMMARY:** The invention named in this  
notice is owned by agencies of the  
United States Government and is  
available for licensing in the United

States (U.S.) in accordance with 35  
U.S.C. 207, and is available for  
cooperative research and development  
agreements (CRADAs) in accordance  
with 15 U.S.C. 3710a, to achieve  
expeditious commercialization of  
results of federally funded research and  
development. A provisional patent  
application has been filed. In addition,  
the invention is protected by copyright  
registration. A Patent Cooperation  
Treaty (PCT) application and national  
stage foreign patent applications  
claiming priority to the Patent  
Cooperation Treaty (PCT) application  
are expected to be filed within the  
appropriate deadlines to extend market  
coverage for U.S. companies and may  
also be available for licensing.

**ADDRESSES:** Licensing and CRADA  
information, and information related to  
the technology listed below, may be  
obtained by writing to Suzanne Seavello  
Shope, J.D., Technology Licensing and  
Marketing Scientist, Technology  
Transfer Office, Centers for Disease  
Control and Prevention (CDC), Mailstop  
K-79, 4770 Buford Highway, Atlanta,  
GA 30341, telephone (770)488-8613;  
facsimile (770)488-8615; or e-mail  
[sshope@cdc.gov](mailto:sshope@cdc.gov). A signed Confidential  
Disclosure Agreement (available under  
Forms at [www.cdc.gov/tto](http://www.cdc.gov/tto)) will be  
required to receive copies of  
unpublished patent applications and  
other information.

**Software**

*Computer Software for Automating  
Permeation Testing Data Analysis*

Data analysis for chemical protective  
clothing (CPC) permeation testing  
involves a number of equations and  
experimental factors. Experimenter bias  
and possible calculation errors are  
critical issues when determining  
permeation parameters. In order to  
compare results among different  
laboratories and manufacturers, the  
normalized breakthrough time is  
required since it is not dependent on the  
detection limits of the analytical system.  
However, calculating the normalized  
breakthrough time requires the use of  
polynomial curve fitting, polynomial  
derivatives, and quadratic equations.  
Solving these equations, without a  
computer program, would be very  
difficult. Therefore, a unique computer  
program using Microsoft Visual C++,  
referred to as "Permeation Calculator",  
has been developed at the National  
Institute for Occupational Safety and  
Health/National Personal Protective  
Technology Laboratory (NIOSH/NPPTL)  
to calculate the permeation parameters.  
The program imports data and then  
calculates the permeation parameters;